Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma
DJ Betting, RE Yamada, K Kafi, J Said… - Journal of …, 2009 - journals.lww.com
The anti-CD20 monoclonal antibody rituximab (Rituxan) has become a mainstay in the
treatment of B cell non-Hodgkin lymphomas. The mechanisms of action for rituximab include
antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity, and
apoptosis induction. Combination of anti-CD20 antibodies with immunostimulatory agents
may improve their efficacy via enhancement of one or more of these mechanisms. Toll-like
receptor 9 agonist CpG oligodeoxynucleotides administered systemically have been studied …
treatment of B cell non-Hodgkin lymphomas. The mechanisms of action for rituximab include
antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity, and
apoptosis induction. Combination of anti-CD20 antibodies with immunostimulatory agents
may improve their efficacy via enhancement of one or more of these mechanisms. Toll-like
receptor 9 agonist CpG oligodeoxynucleotides administered systemically have been studied …
